ProKidney is trading 6.41% down now at $1.31 after reporting a $0.15 quarterly loss versus the $0.13 consensus estimate and $0.15 million in revenue, missing estimates by 31.82%.
- August 10 results showed Q2 net loss widening to $46.4 million, while R&D spending increased to $36.1 million.
- Completed Phase 3 enrollment is a milestone, but accelerated-approval results are not expected until Q2 2027.